Outcome by age and CD20 expression in precursor B-cell ALL: pre-rituximab era
| Age (y)/parameter . | Hyper-CVAD . | P* . | VAD/CVAD . | P* . | ||||
|---|---|---|---|---|---|---|---|---|
| No. . | Percent at 3 yrs . | No. . | Percent at 3 yrs . | |||||
| CD20 neg (n = 77) . | CD20 pos (n = 66) . | CD20 neg (n = 56) . | CD20 pos (n = 54) . | |||||
| < 30 | ||||||||
| No. | 50 | 30 | 20 | — | 42 | 22 | 20 | — |
| % CR | 100 | 100 | NS | 77 | 75 | NS | ||
| % ED | — | — | — | — | — | — | ||
| % Fail | — | — | — | 18 | 10 | NS | ||
| % Relapse | 33 | 68 | .02 | 35 | 80 | .01 | ||
| % Die in CR | — | — | NS | — | 13 | NS | ||
| CRD | 68 | 22 | .006 | 65 | 15 | .03 | ||
| Survival | 85 | 35 | .009 | 50 | 35 | NS | ||
| 31-59 | ||||||||
| No. | 68 | 34 | 34 | — | 45 | 19 | 26 | — |
| % CR | 94 | 94 | NS | 74 | 92 | .09 | ||
| % ED | — | 3 | NS | — | 4 | — | ||
| % Fail | 6 | 3 | NS | 21 | 4 | .07 | ||
| % Relapse | 41 | 60 | NS | 64 | 63 | NS | ||
| % Die in CR | 9 | 6 | NS | 21 | 30 | NS | ||
| CRD | 56 | 30 | .01 | 18 | 18 | NS | ||
| Survival | 54 | 28 | .04 | 15 | 30 | NS | ||
| ≥ 60 | ||||||||
| No. | 25 | 12 | 13 | — | 23 | 15 | 8 | — |
| % CR | 83 | 85 | NS | 47 | 75 | NS | ||
| % ED | — | 15 | NS | 20 | — | NS | ||
| % Fail | 16 | — | NS | 33 | 13 | NS | ||
| % Relapse | 40 | 55 | NS | 71 | 83 | NS | ||
| % Die in CR | 20 | 11 | NS | 29 | 17 | NS | ||
| CRD | 43 | 0 | NS | 35 | 16 | NS | ||
| Survival | 20 | 20 | NS | 8 | 12 | NS | ||
| Age (y)/parameter . | Hyper-CVAD . | P* . | VAD/CVAD . | P* . | ||||
|---|---|---|---|---|---|---|---|---|
| No. . | Percent at 3 yrs . | No. . | Percent at 3 yrs . | |||||
| CD20 neg (n = 77) . | CD20 pos (n = 66) . | CD20 neg (n = 56) . | CD20 pos (n = 54) . | |||||
| < 30 | ||||||||
| No. | 50 | 30 | 20 | — | 42 | 22 | 20 | — |
| % CR | 100 | 100 | NS | 77 | 75 | NS | ||
| % ED | — | — | — | — | — | — | ||
| % Fail | — | — | — | 18 | 10 | NS | ||
| % Relapse | 33 | 68 | .02 | 35 | 80 | .01 | ||
| % Die in CR | — | — | NS | — | 13 | NS | ||
| CRD | 68 | 22 | .006 | 65 | 15 | .03 | ||
| Survival | 85 | 35 | .009 | 50 | 35 | NS | ||
| 31-59 | ||||||||
| No. | 68 | 34 | 34 | — | 45 | 19 | 26 | — |
| % CR | 94 | 94 | NS | 74 | 92 | .09 | ||
| % ED | — | 3 | NS | — | 4 | — | ||
| % Fail | 6 | 3 | NS | 21 | 4 | .07 | ||
| % Relapse | 41 | 60 | NS | 64 | 63 | NS | ||
| % Die in CR | 9 | 6 | NS | 21 | 30 | NS | ||
| CRD | 56 | 30 | .01 | 18 | 18 | NS | ||
| Survival | 54 | 28 | .04 | 15 | 30 | NS | ||
| ≥ 60 | ||||||||
| No. | 25 | 12 | 13 | — | 23 | 15 | 8 | — |
| % CR | 83 | 85 | NS | 47 | 75 | NS | ||
| % ED | — | 15 | NS | 20 | — | NS | ||
| % Fail | 16 | — | NS | 33 | 13 | NS | ||
| % Relapse | 40 | 55 | NS | 71 | 83 | NS | ||
| % Die in CR | 20 | 11 | NS | 29 | 17 | NS | ||
| CRD | 43 | 0 | NS | 35 | 16 | NS | ||
| Survival | 20 | 20 | NS | 8 | 12 | NS | ||
VAD, vincristine, Adriamycin, dexamethasone; CVAD, cyclophosphamide, VAD; hyper-CVAD, hyper-fractionated cyclophosphamide, vincristine, Adriamycin, dexamethasone; CR, complete remission; ED, induction death; Fail, resistance to induction chemotherapy; CRD, complete remission duration; y, years.
P values represent significance levels of comparison of CD20 negative versus CD20 positive within each subset.